News Search Results
Feb 17, 2026, 10:45 ET 2D Materials Market Surges to USD 10.2 Billion by 2033, Propelled by 15.8% CAGR - Verified Market Reports®
Electronics and SemiconductorsEnergy and PowerAerospace and DefenseAutomotiveHealthcare and BiotechnologyBy FunctionalityThermal ConductivityElectrical ConductivityMechanical StrengthOptical
More news about: Verified Market Reports
Feb 17, 2026, 09:01 ET MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall
More news about: MetaVia Inc.
Feb 17, 2026, 09:00 ET Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced that the independent Data Safety
More news about: Diakonos Oncology
Feb 17, 2026, 09:00 ET BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San
More news about: BioMarin Pharmaceutical Inc.
Feb 17, 2026, 08:30 ET Amorphical to Present Long-Term Phase 2 Crohn's Disease Data at the 21st Congress of ECCO
United States.About AmorphicalAmorphical is a biotechnology company advancing a new class of nano-amorphous mineral pharmacologic agents. Leveraging a proprietary, nature-inspired platform, Amorphical aims
More news about: Amorphical
Feb 17, 2026, 08:00 ET Resurrect Bio announces $8.1M initial close of Series A led by Corteva
LONDON, Feb. 17, 2026 /PRNewswire/ -- Resurrect Bio, a biotechnology company revolutionizing agriculture by equipping crops with genetic defenses against disease, today announced the successful initial closing of its Series
More news about: Resurrect Bio
Feb 17, 2026, 08:00 ET GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership
17, 2026 /PRNewswire/ -- GelMEDIX, Inc., a biotechnology company developing regenerative therapies to restore vision, announced today the completion of a $13 million seed financing led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels,
More news about: GelMEDIX
Feb 17, 2026, 07:30 ET Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Feb 17, 2026, 07:00 ET Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
million people in the U.S. currently have MS.2About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Feb 17, 2026, 06:59 ET Q32 Bio Announces $10.5 Million Registered Direct Offering
WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced a $10.5
More news about: Q32 Bio
Feb 17, 2026, 02:25 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.Details of the case: Inovio describes itself as a "biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: THE ROSEN LAW FIRM, P. A.
Feb 16, 2026, 10:46 ET Genotyping Market to Reach $61.6 Billion by 2033 Globally, at 13.8% CAGR: Allied Market Research
Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, and Others), Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics and Others), and End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, and Others):
More news about: Allied Market Research
Feb 16, 2026, 10:01 ET Pyrogen Testing Market to Reach $3.6 billion, Globally, by 2033 at 8.4% CAGR: Allied Market Research
that aligns closely with human physiology.The pharmaceutical and biotechnology companies segment to maintain its lead position during the forecast period By end user, the pharmaceutical and biotechnology companies segment accounted for the largest share in 2022, contributing to
More news about: Allied Market Research
Feb 16, 2026, 10:00 ET Lilly to participate in TD Cowen's 46th Annual Health Care Conference
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 16, 2026, 08:00 ET USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 16, 2026, 06:45 ET Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 13, 2026, 17:36 ET QURE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against uniQure N.V.
investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases.
More news about: Robbins LLP
Feb 13, 2026, 16:15 ET Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public
More news about: Nektar Therapeutics
Feb 13, 2026, 16:01 ET AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Feb 13, 2026, 15:00 ET Sphingolipids Market Forecast 2025-2035: Global Value to Reach USD 1,145.6 Million by 2035 at 5.1% CAGR
Bioparticles; Croda International (SphingoCare™); Merck KGaA; CordenPharma International; Lipoid GmbH; Biosynth; LARODAN AB; Santa Cruz Biotechnology, Inc.; Creative Enzymes; and others.Croda's SphingoCare™ range highlights ongoing expansion in cosmetic-grade sphingolipids and ceramide-based
More news about: Future Market Insights
Feb 13, 2026, 10:30 ET Cleanroom Technologies Market worth $ 12.93 billion by 2031 | MarketsandMarkets™
technological, and industry-specific aspects, are collectively driving the growth of cleanroom technologies. Manufacturers of pharmaceuticals, biotechnology, and medical devices are investing in advanced contamination-control systems, such as isolators, modular cleanrooms, and real-time monitoring solutions,
More news about: MarketsandMarkets
Feb 13, 2026, 09:12 ET Soin Neuroscience and Lilac Biosciences Launch Collaboration to Study RNA Signatures in Pain and Neuromodulation
PROVIDENCE, R.I. and DAYTON, Ohio, Feb. 13, 2026 /PRNewswire/ -- Lilac Biosciences, a biotechnology company spun out of the Giuliani RNA Center at Brown University, developing quantitative RNA-based analytical tools, announced a research collaboration
More news about: Soin Neuroscience
Feb 13, 2026, 08:58 ET Intensity Therapeutics Announces Reverse Stock Split
Feb. 13, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Feb 13, 2026, 08:31 ET Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
Lunai BioworksLunai Bioworks (NASDAQ: LNAI) is an AI-powered biotech and biodefense company pioneering safe and responsible generative biotechnology. Leveraging advanced machine learning and proprietary phenotypic and neurotoxicity datasets, Lunai is redefining how artificial intelligence can
More news about: Lunai Bioworks Inc.
Feb 13, 2026, 08:31 ET MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
CAMBRIDGE, Mass., Feb. 13, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strong global intellectual property portfolio supporting lead asset
More news about: MetaVia Inc.